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Infantile spasms (IS) and Lennox–Gastaut syndrome
(LGS) are epileptic encephalopathies characterized by
early onset, intractable seizures, and poor develop-
mental outcomes. De novo sequence mutations and
copy number variants (CNVs) are causative in a subset
of cases. We used exome sequence data in 349 trios
with IS or LGS to identify putative de novo CNVs. We
confirm 18 de novo CNVs in 17 patients (4.8%), 10 of
which are likely pathogenic, giving a firm genetic diag-
nosis for 2.9% of patients. Confirmation of exome-
predicted CNVs by array-based methods is still
required due to false-positive rates of prediction algo-
rithms. Our exome-based results are consistent with
recent array-based studies in similar cohorts and high-
light novel candidate genes for IS and LGS.
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The epileptic encephalopathies (EEs) are a devastatinggroup of epilepsies in which epileptic activity and
seizures contribute to cognitive impairment or regres-
sion.1 Most EEs begin in infancy or early childhood and
are associated with poor developmental outcome.
Although the cause is unknown in the majority of cases,
recent studies confirm that de novo mutations and copy
number variants (CNVs) play an important role.2,3 We
recently reported exome sequencing data in 264 parent–
proband trios with infantile spasms (n 5 149) or Len-
nox–Gastaut syndrome (LGS; n 5 115) without syn-
dromic features or magnetic resonance imaging (MRI)
abnormalities from the Epilepsy Phenome/Genome Pro-
ject (EPGP) cohort, identifying likely pathogenic, de
novo sequence changes in >10% of patients.2 Here we
report results of copy number analysis derived from the
exome data of this cohort and 85 additional patients to
further elucidate the genetic architecture of these paradig-
matic EEs. Our exome-based CNV calling yields similar
results to array-based studies for confirmed, de novo,
likely pathogenic CNVs.
Patients and Methods
Samples
Probands and family members were collected as part of the
EPGP cohort (Supplementary Table 1) as described previ-
ously2,4 with approval by site-specific institutional review
boards; 1,047 individuals comprising 349 parent–child trios
were included in the present analysis. Of these, 264 were previ-
ously analyzed for de novo single nucleotide variants (SNVs).2
Prior clinical CNV testing included chromosome microarray
and/or karyotype analysis in 131 of 349 patients (38% of
cohort). Detailed inclusion criteria have been published4;
briefly, participants were required to have electroencephalo-
graphic findings consistent with LGS (slow or disorganized
background, and slow spike and wave < 2.7Hz or generalized
paroxysmal fast activity) or infantile spasms (IS; hypsarrhyth-
mia, hypsarrhythmia variant, or electrodecremental discharge).4
Exclusion criteria included evidence of a known genetic syn-
drome or chromosome abnormality. Extensive phenotype analy-
sis of patients enrolled in the study are published elsewhere5
(and Madou et al, manuscript in preparation). All available
clinical records were re-reviewed for those patients found to
have a de novo CNV, and evidence of syndromic features was
often noted upon reexamination of the medical records.
CNV Calling and Validation
CNVs were detected by analyzing exome data using the CoNI-
FER pipeline, a depth-of-coverage–based algorithm using the
conifer-tools package, which implements DNACopy.6,7 Briefly,
exome reads were mapped to exons and 300bp flanking
sequence using mrsFAST. RPKM (mapped reads per kilobase
per million reads) values were calculated, and the first 30 singu-
lar value decomposition (SVD) components were removed to
minimize systematic noise and bias. The following filtering
criteria were applied: CNVs of 3 to 5 probes average
SVD-transformed signal > 1; CNVs of 6 probes, average
signal > 0.5. CNVs >50% in repetitive or duplicated genomic
space were removed. CNV calls were manually curated, and
curated calls were compared to control CNV data sets to filter
out common CNVs present in >1% of the general population.
Control CNV data sets included (1) CNV calls from the ARIC
(Atherosclerosis Risk in Communities) study (n 5 11,305)
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analyzed using Affymetrix AFFY_6.0 single nucleotide polymor-
phism (SNP) microarray; and (2) CNV calls from the National
Heart, Lung, and Blood Institute GO Exome Sequencing Pro-
ject (ESP, n 5 2,972) from CoNIFER analysis of exome
sequence data. CoNIFER-predicted de novo CNVs and a sub-
set of predicted large (>500kb), inherited CNVs were validated
using oligonucleotide (Agilent Technologies, Santa Clara, CA)
and/or SNP (HumanCore 12v1; Illumina, San Diego, CA; n 5
295,393 probes) microarray. De novo CNVs were considered
pathogenic if the CNV (or largely overlapping CNV) was pre-
viously associated with epilepsy or related neurodevelopmental
disorders or contained a known epilepsy gene.
Results
CNV Discovery and Validation
As CNV detection from exome data is still an emerging
technique, we initially performed comprehensive valida-
tion studies in 43 probands to estimate our overall vali-
dation rate for CoNIFER calls in this data set. We vali-
dated 53 of 80 (66%) predicted inherited CNVs,
consistent with our previous studies8 (Supplementary
Table 2). Twenty-four were paternally inherited and 29
were maternally inherited, with a size range of 5.2kb to
8.8Mb (mean 5 377kb). For the same 43 probands, we
validated 5 of 21 (24%) predicted de novo CNVs (Sup-
plementary Table 3). The lower validation rate is not
unexpected, given that any false-positive call in a pro-
band will appear to be de novo, whereas inherited CNV
predictions are supported by the same predicted CNV in
2 individuals (proband and 1 parent).
As the majority of causative CNVs in this cohort
were expected to be de novo, we targeted the remainder
of our validation studies to predicted de novo CNVs.
We confirmed a total of 18 de novo CNVs in 17
patients (Table 1). The de novo CNVs ranged in size
from 94kb to 16Mb and involved 1 to 163 genes. Nota-
bly, none of these 17 individuals had clearly pathogenic
de novo SNVs by exome sequencing. In 10 patients, the
de novo CNV(s) was likely pathogenic based on size,
previous association with epilepsy, or gene content.9 One
pathogenic CNV (15q11 dup) recurred in 3 cases. In 7
patients, the de novo CNV was of uncertain clinical sig-
nificance (see Table 1).
Because whole genome array comparative genome
hybridization was used to validate de novo CNVs, we
also confirmed a large number of inherited CNVs across
the cohort. We confirmed 69 inherited CNVs in 54 indi-
viduals ranging from 5.2kb to 8.8Mb (mean 5 305kb;
Supplementary Table 4). Eight individuals (2.3%) each
had an inherited CNV >500kb; 4 (1.2%) of these were
>1Mb (Table 2). We also looked specifically for inher-
ited CNVs within 3 recurrent deletion regions that have
been previously associated with risk for epilepsy10,11:
15q11.2, 15q13.3, and 16p13.11. Two patients had
inherited deletions of 15q11.2 that may have contributed
to their phenotype; another 2 patients each had a small,
inherited duplication within the 16p13.11 region of
uncertain significance. Aside from the large 15q11-q13
duplications described above, there were no additional
CNVs within the 15q13.3 region. Although de novo
CNVs are more likely to be pathogenic,12 it is possible
that 1 or more of the inherited CNVs in our cohort was
contributory. Three individuals with rare inherited CNVs
had a pathogenic SNV, and 1 had a de novo 15q11
duplication, making it less likely that the inherited CNV
was causative (see Table 2).
There were 540 unique genes within the 18 de
novo CNV regions in our cohort (Supplementary Table
5), 3 of which were known EE genes: SCN1A, SCN2A,
and GABRB3. All 5 individuals with CNVs involving
these genes had phenotypes consistent with those
described for the CNVs they carried (Supplementary
Table 7). Eight additional genes (GLIS3, KIAA1324L,
NIPA1, PLCG2, RCL1, RFX3, SPG7, YWHAG) within
de novo CNV regions were also found to have a de novo
sequence variant by trio exome sequencing in the same
cohort (see Supplementary Table 5, Allen et al,2 and
unpublished data); these cannot be regarded as confirmed
EE genes, but finding both a de novo SNV and a de
novo CNV involving each of them suggests that follow-
up in a larger cohort is warranted. In addition, 3 and 30
genes within de novo CNVs were found to have de novo
mutations by trio exome sequencing in intellectual dis-
ability13,14 and autism,15–18 respectively; these genes may
warrant follow-up given the overlapping genetic suscepti-
bility of these disorders.
Discussion
We detected CNVs from exome sequencing data in 349
trios from patients with IS or LGS. We confirmed 18 de
novo CNVs in 17 of 349 probands (4.8%), providing a
definitive diagnosis in 2.9% of patients and a possible
explanation for another 2.0%. Notably, 38% of the cur-
rent cohort had already undergone karyotype and/or
chromosome microarray testing prior to enrollment in
the study and had not arrived at a diagnosis through
clinical testing. Evaluation of patients without prior
screening may result in a higher yield; we observed a de
novo CNV in 5.6% of the 218 participants in our
cohort without previous clinical testing. These results are
similar to our prior studies in a broader spectrum of EE,
where 4.1% had a definitely pathogenic CNV,3 and to
our recently reported findings in a large clinically ascer-
tained cohort with a broad range of epilepsy diagnoses,
where 5% of cases had a causative CNV.19
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Three individuals each had a de novo duplication
consistent with 15q11q13 duplication syndrome, charac-
terized by hypotonia, seizures, developmental delay, and
behavior problems. A late onset LGS phenotype has been
described in some patients. Other de novo CNVs in our
cohort that have been previously associated with epilepsy
include 7q11 deletion, 9p terminal deletion, 2q24 dupli-
cation, and SCN1A deletion. One patient harbored a de
novo intragenic deletion of the GPHN gene, which enco-
des a protein that is responsible for the clustering of gly-
cine and c-aminobutyric acid receptors at inhibitory syn-
apses. Inherited or de novo deletions involving GPHN
were recently described in 6 patients with autism, schizo-
phrenia, or seizures.20 The deletion in our patient is the
largest of those described and also involves the FAM17D
and MIPP5 genes.
Comparison of the genes within de novo CNV
regions in our cohort to those in which at least 1 other
patient in this cohort had a de novo sequence variant
identifies several novel candidate genes that deserve
follow-up in a larger cohort. Furthermore, several
patients harbor de novo CNVs involving only 1 to 4
genes. Although these CNVs are of uncertain signifi-
cance, identification of de novo SNVs in the same genes
encompassed by certain CNVs would support the finding
that these CNVs are related to disease.
In the large EPGP cohort of IS and LGS patients,
the addition of this CNV data to the de novo SNV find-
ings shows that a definitive genetic diagnosis can be
reached in >15% of cases for which there was previously
no known cause. As whole exome sequencing is becom-
ing widely used, one might ask whether CNV data can
be efficiently and reliably extracted in a clinical setting,
thus bypassing the need for array-based CNV assays. Our
experience, especially as shown by the false-positive rate,
suggests that array-based technologies are currently still
required. A logical clinical approach to a patient with IS
or LGS of unknown etiology should include a chromo-
some microarray for patients with epilepsy and additional
findings such as abnormal MRI, developmental delays,
or dysmorphic features, followed by an epilepsy-focused
targeted gene panel and then whole exome sequencing in
TABLE 2. Selected Inherited CNVs
Trio CNV (inheritance) Size,
kb
No. of Genes;
Possible EE
Candidates
Causative
d.n. SNV?
Validation
Platform
Large [>500kb] inherited CNVs
jp 2p22 dup (paternal) 620 3 genes; BIRC6,
TTC27, LTBP1
No SNP
ip 17q dup (paternal) 737 13 genes No CGH
ad 10q21 del (maternal) 858 1 gene; PCDH15 No SNP
jg 4p16 dup (maternal) 885 5 genes WDR45 frameshift SNP
ki 7q11 dup (paternal) 1,000 9 genes DNM1 missense SNP
dg Xp22 del (paternal) 1,900 8 genes ALG13 missense h.c.
bj Xp22 dup (maternal) 2,000 9 genes No h.c.
gq 1q31 dup (paternal) 8,800 23 genes No; de novo
15q11 dup
CGH, SNP
Recurrent CNV regions previously associated with epilepsy
j 16p13 dup (paternal) 30 NTAN1, PDXDC1
(16p13.11)
No h.c.
r 16p13 dup (maternal) 58 ABCC1, ABCC6
(16p13.11)
No h.c.
d 15q11.2 del (maternal) 213 NIPA2, CYFIP1 No h.c.
in 15q11.2 del (paternal) 213 NIPA2, CYFIP1 No SNP
CGH 5 comparative genome hybridization; CNV 5 copy number variant; d.n. 5 de novo; EE 5 epileptic encephalopathy; h.c.
5 high-confidence CNV call by CoNIFER; SNP 5 single nucleotide polymorphism; SNV 5 single nucleotide variant.
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cases that remain undiagnosed. As prediction algorithms
improve, exome and eventually whole genome sequenc-
ing will provide a genetic diagnosis in an even greater
proportion of patients in the clinical setting, improving
medical management and genetic counseling in this
patient population.
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